ALBO News and Press, Albireo Pharma Inc. From 10/03/22

Summary Albireo Pharma, Inc. is expanding its Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. The company is poised to report topline data for the Phase 3 (ASSERT) trial for Alagille syndrome this Fall. Meanwhile, the firm inked a lucra...

Albireo Pharma, Inc. ( NASDAQ: ALBO ) added ~7% in the morning hours Thursday after the biotech focused on liver diseases announced an agreement with asset manager Sagard Healthcare Partners to sell royalties from the company's FDA-approved pruritus therapy Bylvay. Per...

Upfront payment for continued clinical development and commercialization of Bylvay ® Sagard to receive a mid-single digit average royalty rate on Bylvay sales No liens against Bylvay intellectual property Right to buy out Sagard’s ...

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September ...

Albireo Pharma ( NASDAQ: ALBO ) said the Italian Medicines Agency has enabled reimbursed access to Bylvay (odevixibat) to treat all types of patients with progressive familial intrahepatic cholestasis (PFIC) in Italy. PFIC is a rare progressive, liver disease. ...

Positive Agenzia Italiana del Farmaco (AIFA) d ecision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that affects young children and causes progressive, life-threatening liver disease ...

Following the public offering, Mirum is in an excellent financial position to accelerate both the Livmarli launch and the clinical development pipeline. The biggest value driver is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 ...

Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...

Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...

Shares of small-cap liver disease treatments maker Albireo Pharma ( NASDAQ: ALBO ) fell 26.1% to $18.42 in Tuesday early trading, despite the company reporting a jump in quarterly revenue due to sales of liver disease-induced itchy skin drug Bylvay. The company also cut ...